Please wait



(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001857948 XXXXXXXX LIVE 2 Common stock, par value $0.0001 per share 03/02/2026 false 0001808805 63909J108 Nautilus Biotechnology, Inc. 2701 Eastlake Avenue East Seattle WA 98102 Parag Mallick 206-333-2001 2701 Eastlake Avenue East Seattle WA 98102 Zachary B. Myers 650-493-9300 Wilson Sonsini Goodrich & Rosati 650 Page Mill Road Palo Alto CA 94304 0001857948 N Parag Mallick PF N X1 22357411.00 200000.00 22357411.00 200000.00 22557411.00 N 17.6 IN Items 7, 9, and 11 above consists of 20,493,392 shares of Common Stock directly owned by Parag Mallick and a total of 1,864,019 shares of Common Stock issuable upon exercise of options. Of such options to purchase shares, 1,234,018 shares shall be vested and exercisable within 60 days of March 2, 2026. Items 8, 10, and 11 above consists of 200,000 shares of Common Stock directly owned by The Dream Finder Foundation (the "Foundation"). Dr. Mallick and his spouse share voting and dispositive power over the shares held by the Foundation and Dr. Mallick is the President of the Foundation. Item 13 above is based on the quotient obtained by dividing (a) the aggregate number of shares of Common Stock beneficially owned by Dr. Mallick by (b) the sum of (i) 126,564,473 shares of Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission on February 26, 2026, and (ii) the 1,864,019 shares of Common Stock issuable upon exercise of options held by Dr. Mallick. The aggregate number of shares of Common Stock beneficially owned by Dr. Mallick as set forth in clauses "(a)" and "(b)" of this footnote are treated as outstanding shares of Common Stock only for the purpose of computing the percentage ownership of Dr. Mallick. Common stock, par value $0.0001 per share Nautilus Biotechnology, Inc. 2701 Eastlake Avenue East Seattle WA 98102 This Amendment No. 2 (this "Amendment") amends and supplements the Schedule 13D filed on June 16, 2021, as amended by Amendment No. 1 filed on March 5, 2025 (the "Schedule 13D") by Parag Mallick (the "Reporting Person") relating to the Common Stock of Nautilus Biotechnology, Inc. (the "Issuer"). Information reported in the Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Schedule 13D. All references in the Schedule 13D and this Amendment shall be deemed to refer to the Schedule 13D as amended and supplemented by this Amendment. As of the date of this Schedule 13D, the Reporting Person beneficially owns an aggregate of 22,557,411 shares of Common Stock, or 17.6% of the Issuer's outstanding shares of Common Stock. The beneficial ownership percentages used in this Schedule are calculated based on a total of 126,564,473 shares of Common Stock outstanding as of February 19, 2026 plus 1,864,019 shares of Common Stock issuable upon exercise of options held by the Reporting Person. 1,234,018 of the Reporting Person's options to purchase shares of Common Stock are exercisable within 60 days of March 2, 2026. The unvested options to purchase shares of Common Stock vest over time subject to the Reporting Person's continued service through each vesting date. If, during the period beginning three months before a change in control through the one-year anniversary of a change in control, the Reporting Person's employment with the Issuer is terminated either (x) by the Issuer without cause, and excluding by reason of the Reporting Person's death or disability or (y) by the Reporting Person for good reason, then 100% of any unvested shares shall immediately vest. The Reporting Person and the Reporting Person's spouse share voting and dispositive power with respect to 200,000 shares of Common Stock owned by the Foundation. The Reporting Person has sole voting and dispositive power with respect to 20,493,392 shares of Common Stock and options to purchase 1,864,019 shares of Common Stock. On March 2, 2026, the Reporting Person was granted an option to purchase 280,000 shares of the Issuer's Common Stock. Except for such option grant, the Reporting Person has not effected any transactions in the Common Stock during the past 60 days. Parag Mallick /s/ Matthew Murphy Matthew Murphy/Attorney-in-fact 03/04/2026